Trial Profile
Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions
- Acronyms XaMINA
- Sponsors Bayer
- 26 May 2022 Results published in the Advances in Therapy
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Planned End Date changed from 31 Oct 2019 to 20 Nov 2019.